Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer - sprookjes - yvandenbroek - TriplyDB

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

http://www.wikidata.org/entity/Q24649684

about

Critical appraisal of trastuzumab in treatment of advanced stomach cancer Novel immunotherapeutic strategies of gastric cancer treatment A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.Targeting metastatic upper gastrointestinal adenocarcinomas Gastric cancer and the epoch of immunotherapy approaches Targeted therapy for esophagogastric cancers: a review Novel investigational drugs for gastric cancer.New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.Targeted therapies for metastatic esophagogastric cancer Molecular imaging for guiding oncologic prognosis and therapy in esophageal adenocarcinoma.Molecular targeted agents for gastric and gastroesophageal junction cancer.Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Clinical management of advanced gastric cancer: the role of new molecular drugs.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Targeted therapy in esophageal cancer.Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.

P2860

Q24604411-2956A1ED-1946-47B8-B3AA-0D3567377F30 Q27011232-E1768AC0-2D93-4906-88DA-0A7A13454D6A Q33407672-ECEBEFC4-A243-4CF6-96D5-4411B61E9634 Q35000785-F1BA7DB3-2E75-4E25-A50E-8154EB9D16E4 Q35625349-98D59A40-27B6-4E69-8FC4-FA88BC0E5CE5 Q36039645-DE7DC8F2-AA53-4346-A3EB-BF38A74E11C5 Q37494644-23225DBF-59B4-4F43-84FA-EFC2199116C3 Q37725910-054E56C1-EA56-47F7-8709-14B050DE7EE2 Q37836513-50F32EAC-1863-4508-8FEE-605AF9F168AD Q37876081-CED13394-EBFC-4957-A694-713A573C2164 Q37962816-B870704A-AEBD-45AF-8EF6-D8BF245BCB82 Q38161727-148A5DF0-29A5-4682-9943-7EC5094BC5C4 Q38199128-9FDF32C3-833F-4A14-AB4B-3A8541E94766 Q38221886-B907D738-FEBB-4348-805A-AA5C83F148BE Q38263841-32BA99D6-3A8C-4845-9C2D-B7374DCE604A Q38578404-BE8F831F-A367-4144-88CB-564CC5B5919B Q38632917-B8238921-3DE5-4FDC-AFD6-0B5253CD23C3 Q38720829-09552BF2-D071-4AD3-B92E-BB0CC8E462C7 Q38741042-81B64DB0-A0B3-41BE-8659-DEC027EDCFE4 Q38970911-936F719B-0888-4F7A-9B08-1C56EE3D4E73 Q42520266-608DEC7C-43A8-4F0A-8A63-73FD7ECA9775 Q42661688-C485B63E-EFFC-4099-AA72-06502D61CE19 Q42769520-99EDCEF0-FA68-4712-A332-BCC90E123C64 Q45202800-7A782A79-40A5-49C2-B541-DFA0D13238E7 Q48124426-A5ADC87C-127C-4FA9-82A6-30CEF1350E19 Q54494748-29A34DA5-75BF-47D9-85E0-DC82461C4177 Q54786239-351D6AE8-780E-4499-B44B-280A057B3B5D

P2860

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

http://www.wikidata.org/entity/Q24649684

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@ast

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@en

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@nl

type

label

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@ast

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@en

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@nl

prefLabel

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@ast

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@en

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@nl

P1433

Q24649684-B954720A-F916-481F-937D-C476A001E7AE

P1476

Q24649684-C959A553-8100-4E4A-8736-9B17E2A64DDE

P2093

Q24649684-336F7D80-B06F-4855-9609-B2DD76836A22

Q24649684-3E761812-4B06-485C-9CE2-47AE55E49CED

Q24649684-4B998EF2-7281-4A64-B095-62B905D5A223

Q24649684-4D9A4F51-EE74-496D-A12D-789C9B46D4C1

Q24649684-BC582381-9D40-4380-A734-A17B37A961D2

Q24649684-DDC0B0B6-7D75-4FA5-9DC2-44188D7BCAF0

Q24649684-E3ABE2EC-B6ED-4FAB-9E93-9AAA4AF6D18A

Q24649684-F94BA1A8-E022-4F77-BD62-F8B87AE81ABB

P2860

Q24649684-0033891C-AECD-4E64-BF4A-5CAEF4F68442

Q24649684-007FDB4F-52F0-4A8E-A97D-64CC6770E7C0

Q24649684-084EE81E-605F-47DD-83C0-9FEF87EFEE72

Q24649684-2A0E5739-7038-4548-A97E-B14C8E2892D5

Q24649684-36DCF009-9C72-46B2-AB5E-3F822E509D7D

Q24649684-4D972E36-26A1-49C2-A0AA-E75B0390E3CA

Q24649684-6F6CB76F-EBB7-43B5-86E9-7328C8C26F96

Q24649684-7051B26B-DB1F-49A9-9D59-F8D627D976E1

Q24649684-70D20742-F281-4A97-A3DB-BF41D737E901

Q24649684-79F92C8D-B6A3-4A4B-8068-6EA686FDCC6C

P2888

Q24649684-6106FC7B-89FB-43D0-B21D-4FE0BEB813D7

P304

Q24649684-41BEB0B1-1686-4E77-9AEB-3270663497B7

P31

Q24649684-EAA72FDD-2091-4073-BC64-65C2B91A6FC4

P356

Q24649684-54D72215-AE12-4ACD-A1FA-7F2E8F23CA21

P407

Q24649684-A1E5ACF6-2922-460C-8436-6EAE2E2316B2

P433

Q24649684-746913E1-2D35-4C4A-AADA-13E714AD8283

P478

Q24649684-6109A8DA-0954-4969-A738-E61583A41354

P50

Q24649684-C6A11B65-4017-4203-83A1-165021AE42BE

Q24649684-C8E21C94-9F32-4355-99A2-8766AF8782B4

P577

Q24649684-3904792A-F112-40BE-9073-E325390B0C82

P5875

Q24649684-64EC3D6C-7CD7-428F-996C-0834AD3E460B

P6179

Q24649684-26C290F9-44C0-40C5-84B1-5926B0F500FA

P698

Q24649684-A4F51021-2BFE-480D-AEC4-829DFB0882D1

P932

Q24649684-B409CFC0-893C-45B5-BE32-06B2D53CB40D

P356

P1433

British Journal of Cancer

P1476

Phase I study of epirubicin, c ...... vanced oesophagogastric cancer

@en

P2093

A Hill

http://www.w3.org/2001/XMLSchema#string

A Wotherspoon

http://www.w3.org/2001/XMLSchema#string

C Lüpfert

http://www.w3.org/2001/XMLSchema#string

J Baselga

http://www.w3.org/2001/XMLSchema#string

J Oates

http://www.w3.org/2001/XMLSchema#string

M Benson

http://www.w3.org/2001/XMLSchema#string

R Kurek

http://www.w3.org/2001/XMLSchema#string

S Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Cell signaling by receptor tyrosine kinases

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis.

P2888

P304

868-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604622

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

Naureen Starling

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24036250

http://www.w3.org/2001/XMLSchema#string

P6179

1052205307

http://www.w3.org/2001/XMLSchema#string

P698

19238629

http://www.w3.org/2001/XMLSchema#string

P932

2538760

http://www.w3.org/2001/XMLSchema#string